Analyst Conference Summary

Amgen
AMGN

conference date: October 22, 2008 @ 2:00 PM Pacific Time
for quarter ending: September 30, 2008 (3rd quarter)


Forward-looking statements

Overview:

Basic data (GAAP) :

Revenues were

Net income was

EPS (earnings per share)

Guidance:

 

Conference Highlights:

 

Q2 revenues in $ millions
Drug
2008
2007
Aranesp
$825
$949
Epogen
622
624
Neulasta
862
734
Neupogen
339
307
Enbrel
841
823
Sensipar
150
108
Vectibix
32
45
Other
21
14
Q3 revenues in $ millions
Drug
2008
2007
Aranesp
$
$
Epogen
Neulasta
Neupogen
Enbrel
Sensipar
Vectibix
Other

 

Q&A:

 

OpenIcon Analyst Conference Summaries Main Page

Amgen Investor Relations page

Search

More Analyst Conference Pages:

 
 ADBE
 AKAM
 ALTR
 AMAT
 AMD
 AMGN
 ANSV
 ATML
 BIIB
 CELG
 CHINA
 CSCO
 DELL
 DNA
 DNDN
 GILD
 GOOG
 HILL
 HPQ
 IBM
 INTC
 JNPR
 LLTC
 MCHP
 MOT
 MRVL
 MSFT
 MXIM
 NAPS
 NOVL
 NVDA
 ORCL
 ONXX
 RACK
 RHT
 STMP
 SUNW
 TXN
 XLNX
 YHOO

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. Before making or terminating an investment you should always verify any factual basis of your decision.

Copyright 2008 William P. Meyers